Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy

Scott T. Avecilla, Chris Ferrell, Wayne L. Chandler, Morayma Reyes Gil

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market for venous thromboembolic prophylaxis and for stroke prevention in atrial fibrillation. While dabigatran has been approved for use without the need for routine therapeutic monitoring, there are clinical scenarios in which monitoring can help guide clinical management. We report herein the application of a recently described plasma-diluted thrombin time (DTI assay) used to monitor intravenous DTI as a useful and easily implemented method to monitor oral DTIs. Copyright

Original languageEnglish (US)
Pages (from-to)572-574
Number of pages3
JournalAmerican Journal of Clinical Pathology
Volume137
Issue number4
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Thrombin Time
Antithrombins
Anticoagulants
Atrial Fibrillation
Therapeutics
Stroke
Dabigatran

Keywords

  • Dabigatran
  • Thrombin inhibitor
  • Thrombin time

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. / Avecilla, Scott T.; Ferrell, Chris; Chandler, Wayne L.; Reyes Gil, Morayma.

In: American Journal of Clinical Pathology, Vol. 137, No. 4, 04.2012, p. 572-574.

Research output: Contribution to journalArticle

@article{1aebc9b2da134c958dc8978356f84a09,
title = "Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy",
abstract = "New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market for venous thromboembolic prophylaxis and for stroke prevention in atrial fibrillation. While dabigatran has been approved for use without the need for routine therapeutic monitoring, there are clinical scenarios in which monitoring can help guide clinical management. We report herein the application of a recently described plasma-diluted thrombin time (DTI assay) used to monitor intravenous DTI as a useful and easily implemented method to monitor oral DTIs. Copyright",
keywords = "Dabigatran, Thrombin inhibitor, Thrombin time",
author = "Avecilla, {Scott T.} and Chris Ferrell and Chandler, {Wayne L.} and {Reyes Gil}, Morayma",
year = "2012",
month = "4",
doi = "10.1309/AJCPAU7OQM0SRPZQ",
language = "English (US)",
volume = "137",
pages = "572--574",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy

AU - Avecilla, Scott T.

AU - Ferrell, Chris

AU - Chandler, Wayne L.

AU - Reyes Gil, Morayma

PY - 2012/4

Y1 - 2012/4

N2 - New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market for venous thromboembolic prophylaxis and for stroke prevention in atrial fibrillation. While dabigatran has been approved for use without the need for routine therapeutic monitoring, there are clinical scenarios in which monitoring can help guide clinical management. We report herein the application of a recently described plasma-diluted thrombin time (DTI assay) used to monitor intravenous DTI as a useful and easily implemented method to monitor oral DTIs. Copyright

AB - New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market for venous thromboembolic prophylaxis and for stroke prevention in atrial fibrillation. While dabigatran has been approved for use without the need for routine therapeutic monitoring, there are clinical scenarios in which monitoring can help guide clinical management. We report herein the application of a recently described plasma-diluted thrombin time (DTI assay) used to monitor intravenous DTI as a useful and easily implemented method to monitor oral DTIs. Copyright

KW - Dabigatran

KW - Thrombin inhibitor

KW - Thrombin time

UR - http://www.scopus.com/inward/record.url?scp=84860548394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860548394&partnerID=8YFLogxK

U2 - 10.1309/AJCPAU7OQM0SRPZQ

DO - 10.1309/AJCPAU7OQM0SRPZQ

M3 - Article

C2 - 22431533

AN - SCOPUS:84860548394

VL - 137

SP - 572

EP - 574

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -